When an insurer labels trigeminal nerve blocks investigational, patients may face brain surgery instead. This essay examines how coverage policy, coding decisions, and actuarial incentives shape care for trigeminal neuralgia and what must change to align patient protection with economic logic.

Sally Neely Nix manages chronic pain with nerve block injections. No opioids. Her insurer calls them experimental. So she built a policy brief and sent it to the CEO. While in extreme pain. Patients shouldn't have to become researchers to access care that works.